Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 6 uppsatser.

Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with a dismal prognosis. Few patients present with disease amenable to resection and chemotherapy is not curative. The incidence of ICC is rising worldwide and new therapeutic approaches are urgently required. Notch signalling is critical for the embryological development and regeneration of the biliary tree in the mammalian liver. Dysregulation of Notch is known to drive tumorigenesis in a range of solid and haematological malignancies and the aim of this work was to define its contribution to the pathogenesis of ICC. Transgenic overexpression of Notch1 has been described to result in the formation of biliary lineage tumours in the liver. I have used resected human tissue, a chemically-induced model of ICC in rat and a novel transgenic murine model in which the tumour suppressor p53 is conditionally deleted from biliary epithelia, to demonstrate that endogenous Notch signalling is acting via the Notch3 receptor to drive tumorigenesis. I use multiple independent methods of Notch3 blockade to establish that Notch3 promotes epithelial cell survival and self-renewal in ICC and demonstrate that Notch3 inhibition significantly attenuates tumour growth in vivo. My data suggest that Notch3 promotes activity through the PI3K/AKT cell survival cascade via a mechanism independent of the effector of canonical Notch, RBPJκ. Given the significant toxicity associated with gamma-secretase inhibitors these findings offer a novel and specific target for further investigation and future therapeutic development in ICC.

Adverse reactions to the antiarrhythmic medication amiodarone are severe, potentially life-threatening, and not rare. One in three patients on long-term therapy experience elevated liver enzymes, and clinically apparent liver toxicity occurs in 1% of patients treated. We report the case of a 76-year-old patient with amiodarone-induced intrahepatic cholestasis and prolonged hyperbilirubinemia despite the discontinuation of the offending agent. Current research hypothesizes that amiodarone leads to hepatic injury both by direct hepatotoxicity and by increasing the likelihood of hepatocytes to create abnormal, toxic metabolites. Increased awareness of such an adverse effect can guide clinicians toward the possible underlying etiologies of prolonged jaundice.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第25199号 / 医博第5085号 / 新制||医||1072(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 川口 義弥, 教授 藤田 恭之, 教授 妹尾 浩 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

Introdução: A atresia biliar (AB) inclui obstrução completas das vias biliares extra-hepáticas e uma colangiopatia intra-hepática progressiva, cirrogênica. A natureza da colangiopatia destes processos permanece obscura. Uma arteriopatia levando a colangiopatia isquêmica explicaria a natureza progressiva da lesão biliar. A imunolocalização do fator de crescimento endotelial vascular A (VEGFA) em ramos arteriais e ductos biliares intra-hepáticos e do porta hepatis dos pacientes com AB sugere isquemia nestas estruturas. A ocorrência de hipóxia hepatobiliar na AB necessita ser esclarecida. Objetivo: Determinar a presença de hipóxia nos fígados de pacientes com AB, analisando a expressão gênica dos fatores induzidos por hipóxia (HIF) -1α e -2α. Métodos: Estudo de amostras de biópsias em cunha coletadas na laparotomia exploradora de pacientes com AB isolada sem IgM+ para citomegalovírus (n= 32) comparando com lactentes com colestase intra-hepática (CIH, n= 09), pareados por idade. Uma amostra foi ultracongelada (análise molecular) e outra, parafinizada (análises histológica e imunoistoquímica). Por PCRq, usando sondas TaqMan®, avaliaram-se as expressões gênicas de: HIF1-α, HIF2-α, proteína quimiotática de monócitos 1 (MCP1) (marcador de fibrose biliar), citoqueratina 19 (CK19) (marcador de colangiócitos). O gene normalizador foi 18S ribossômico. Por morfometria, foram quantificadas as extensões de fibrose e reação ductular. Dados clínico-laboratoriais foram prospectivamente coletados. Resultados: O grupo AB, comparado à CIH, apresentou maior expressão de HIF1-α e HIF2-α. No grupo AB, a expressão do HIF1-α correlacionou-se positivamente com a bilirrubina total (BT) sérica. Dois subgrupos de AB foram detectados quanto à expressão dos HIFs: alta (hiHIF, expressão 3x maior que a mediana da CIH) e baixa (loHIF). Pacientes hiHIF-1α eram mais velhos e com maiores níveis de BT e bilirrubina direta (BD) que loHIF-1α. O subgrupo hiHIF-2α apresentou expressão de CK19 inferior a do loHIF-2α. As demais variáveis foram semelhantes nos subgrupos HIFs. Conclusão: Na AB ocorre hipóxia tecidual hepática. Os dados sugerem a existência de hipóxia tecidual progressiva nos fígados afetados pela AB, associada ao desaparecimento de ductos biliares e à piora do quadro obstrutivo biliar. / Background: Biliary atresia (BA) includes a complete obstruction of the extrahepatic biliary tract and progressive intrahepatic cholangiopathy, and the nature of these processes remains unclear. An arteriopthy, leading to an ischemic cholangiopathy, can be involved. The immunolocalization of vascular endothelial growth factor A (VEGFA) in arterial branches and bile ducts both within the liver and at porta hepatis from patients with BA suggests ischemia in these structures. The occurrence of hypoxia in the hepatobiliary system in BA needs to be elucidated. Aim: To determinate the presence of hypoxia in the livers from patients with BA, by analyzing the gene expression of hypoxia-inducible factor (HIF) -1α and -2α. Methods: Liver biopsy specimens collected at exploratory laparotomy of age-matched patients with isolated, cytomegalovirus IgM-negative BA (n=32) and intrahepatic cholestasis (IHC, n=9) were evaluated. A sample was ultrafrozen (molecular analysis) and the other was paraffin-embedded (for histological and morphometric analyzes). Gene expression of: HIF-1α, HIF-2α, monocyte chemoattractant protein 1 (MCP1) (biliary fibrosis marker) and cytokeratin 19 (CK19) (cholangiocyte marker) were evaluated by PCRq using TaqMan® probes. The normalizing gene was 18S ribosomal. The extents of fibrosis and ductular reaction were assessed by morphometry. Clinical and laboratory data were prospectively collected. Results: There was higher HIF-1α and HIF-2α expression in BA in comparison with IHC. In BA, the HIF-1α expression was positively correlated with total serum bilirubin (TB). Two groups were observable in BA regarding HIFs: higher (hiHIF, considering as cutoff point a value higher than 3x the median of expression in IHC) and lower (loHIF). Patients with hiHIF-1α were older and presented increased levels of TB and direct-reacting serum bilirubin (DB) than loHIF-1α. Patients with hiHIF-2α presented CK19 expression lower than in loHIF-2α. The other variables were similar in subgroups HIFs. Conclusion: In BA there is hypoxia in the liver tissue, which seems to be progressive and associated with the disappearance of bile ducts and worsening biliary obstruction.

Introdução: A atresia biliar (AB) inclui obstrução completas das vias biliares extra-hepáticas e uma colangiopatia intra-hepática progressiva, cirrogênica. A natureza da colangiopatia destes processos permanece obscura. Uma arteriopatia levando a colangiopatia isquêmica explicaria a natureza progressiva da lesão biliar. A imunolocalização do fator de crescimento endotelial vascular A (VEGFA) em ramos arteriais e ductos biliares intra-hepáticos e do porta hepatis dos pacientes com AB sugere isquemia nestas estruturas. A ocorrência de hipóxia hepatobiliar na AB necessita ser esclarecida. Objetivo: Determinar a presença de hipóxia nos fígados de pacientes com AB, analisando a expressão gênica dos fatores induzidos por hipóxia (HIF) -1α e -2α. Métodos: Estudo de amostras de biópsias em cunha coletadas na laparotomia exploradora de pacientes com AB isolada sem IgM+ para citomegalovírus (n= 32) comparando com lactentes com colestase intra-hepática (CIH, n= 09), pareados por idade. Uma amostra foi ultracongelada (análise molecular) e outra, parafinizada (análises histológica e imunoistoquímica). Por PCRq, usando sondas TaqMan®, avaliaram-se as expressões gênicas de: HIF1-α, HIF2-α, proteína quimiotática de monócitos 1 (MCP1) (marcador de fibrose biliar), citoqueratina 19 (CK19) (marcador de colangiócitos). O gene normalizador foi 18S ribossômico. Por morfometria, foram quantificadas as extensões de fibrose e reação ductular. Dados clínico-laboratoriais foram prospectivamente coletados. Resultados: O grupo AB, comparado à CIH, apresentou maior expressão de HIF1-α e HIF2-α. No grupo AB, a expressão do HIF1-α correlacionou-se positivamente com a bilirrubina total (BT) sérica. Dois subgrupos de AB foram detectados quanto à expressão dos HIFs: alta (hiHIF, expressão 3x maior que a mediana da CIH) e baixa (loHIF). Pacientes hiHIF-1α eram mais velhos e com maiores níveis de BT e bilirrubina direta (BD) que loHIF-1α. O subgrupo hiHIF-2α apresentou expressão de CK19 inferior a do loHIF-2α. As demais variáveis foram semelhantes nos subgrupos HIFs. Conclusão: Na AB ocorre hipóxia tecidual hepática. Os dados sugerem a existência de hipóxia tecidual progressiva nos fígados afetados pela AB, associada ao desaparecimento de ductos biliares e à piora do quadro obstrutivo biliar. / Background: Biliary atresia (BA) includes a complete obstruction of the extrahepatic biliary tract and progressive intrahepatic cholangiopathy, and the nature of these processes remains unclear. An arteriopthy, leading to an ischemic cholangiopathy, can be involved. The immunolocalization of vascular endothelial growth factor A (VEGFA) in arterial branches and bile ducts both within the liver and at porta hepatis from patients with BA suggests ischemia in these structures. The occurrence of hypoxia in the hepatobiliary system in BA needs to be elucidated. Aim: To determinate the presence of hypoxia in the livers from patients with BA, by analyzing the gene expression of hypoxia-inducible factor (HIF) -1α and -2α. Methods: Liver biopsy specimens collected at exploratory laparotomy of age-matched patients with isolated, cytomegalovirus IgM-negative BA (n=32) and intrahepatic cholestasis (IHC, n=9) were evaluated. A sample was ultrafrozen (molecular analysis) and the other was paraffin-embedded (for histological and morphometric analyzes). Gene expression of: HIF-1α, HIF-2α, monocyte chemoattractant protein 1 (MCP1) (biliary fibrosis marker) and cytokeratin 19 (CK19) (cholangiocyte marker) were evaluated by PCRq using TaqMan® probes. The normalizing gene was 18S ribosomal. The extents of fibrosis and ductular reaction were assessed by morphometry. Clinical and laboratory data were prospectively collected. Results: There was higher HIF-1α and HIF-2α expression in BA in comparison with IHC. In BA, the HIF-1α expression was positively correlated with total serum bilirubin (TB). Two groups were observable in BA regarding HIFs: higher (hiHIF, considering as cutoff point a value higher than 3x the median of expression in IHC) and lower (loHIF). Patients with hiHIF-1α were older and presented increased levels of TB and direct-reacting serum bilirubin (DB) than loHIF-1α. Patients with hiHIF-2α presented CK19 expression lower than in loHIF-2α. The other variables were similar in subgroups HIFs. Conclusion: In BA there is hypoxia in the liver tissue, which seems to be progressive and associated with the disappearance of bile ducts and worsening biliary obstruction.

Introdução: A atresia biliar (AB) inclui obstrução completas das vias biliares extra-hepáticas e uma colangiopatia intra-hepática progressiva, cirrogênica. A natureza da colangiopatia destes processos permanece obscura. Uma arteriopatia levando a colangiopatia isquêmica explicaria a natureza progressiva da lesão biliar. A imunolocalização do fator de crescimento endotelial vascular A (VEGFA) em ramos arteriais e ductos biliares intra-hepáticos e do porta hepatis dos pacientes com AB sugere isquemia nestas estruturas. A ocorrência de hipóxia hepatobiliar na AB necessita ser esclarecida. Objetivo: Determinar a presença de hipóxia nos fígados de pacientes com AB, analisando a expressão gênica dos fatores induzidos por hipóxia (HIF) -1α e -2α. Métodos: Estudo de amostras de biópsias em cunha coletadas na laparotomia exploradora de pacientes com AB isolada sem IgM+ para citomegalovírus (n= 32) comparando com lactentes com colestase intra-hepática (CIH, n= 09), pareados por idade. Uma amostra foi ultracongelada (análise molecular) e outra, parafinizada (análises histológica e imunoistoquímica). Por PCRq, usando sondas TaqMan®, avaliaram-se as expressões gênicas de: HIF1-α, HIF2-α, proteína quimiotática de monócitos 1 (MCP1) (marcador de fibrose biliar), citoqueratina 19 (CK19) (marcador de colangiócitos). O gene normalizador foi 18S ribossômico. Por morfometria, foram quantificadas as extensões de fibrose e reação ductular. Dados clínico-laboratoriais foram prospectivamente coletados. Resultados: O grupo AB, comparado à CIH, apresentou maior expressão de HIF1-α e HIF2-α. No grupo AB, a expressão do HIF1-α correlacionou-se positivamente com a bilirrubina total (BT) sérica. Dois subgrupos de AB foram detectados quanto à expressão dos HIFs: alta (hiHIF, expressão 3x maior que a mediana da CIH) e baixa (loHIF). Pacientes hiHIF-1α eram mais velhos e com maiores níveis de BT e bilirrubina direta (BD) que loHIF-1α. O subgrupo hiHIF-2α apresentou expressão de CK19 inferior a do loHIF-2α. As demais variáveis foram semelhantes nos subgrupos HIFs. Conclusão: Na AB ocorre hipóxia tecidual hepática. Os dados sugerem a existência de hipóxia tecidual progressiva nos fígados afetados pela AB, associada ao desaparecimento de ductos biliares e à piora do quadro obstrutivo biliar. / Background: Biliary atresia (BA) includes a complete obstruction of the extrahepatic biliary tract and progressive intrahepatic cholangiopathy, and the nature of these processes remains unclear. An arteriopthy, leading to an ischemic cholangiopathy, can be involved. The immunolocalization of vascular endothelial growth factor A (VEGFA) in arterial branches and bile ducts both within the liver and at porta hepatis from patients with BA suggests ischemia in these structures. The occurrence of hypoxia in the hepatobiliary system in BA needs to be elucidated. Aim: To determinate the presence of hypoxia in the livers from patients with BA, by analyzing the gene expression of hypoxia-inducible factor (HIF) -1α and -2α. Methods: Liver biopsy specimens collected at exploratory laparotomy of age-matched patients with isolated, cytomegalovirus IgM-negative BA (n=32) and intrahepatic cholestasis (IHC, n=9) were evaluated. A sample was ultrafrozen (molecular analysis) and the other was paraffin-embedded (for histological and morphometric analyzes). Gene expression of: HIF-1α, HIF-2α, monocyte chemoattractant protein 1 (MCP1) (biliary fibrosis marker) and cytokeratin 19 (CK19) (cholangiocyte marker) were evaluated by PCRq using TaqMan® probes. The normalizing gene was 18S ribosomal. The extents of fibrosis and ductular reaction were assessed by morphometry. Clinical and laboratory data were prospectively collected. Results: There was higher HIF-1α and HIF-2α expression in BA in comparison with IHC. In BA, the HIF-1α expression was positively correlated with total serum bilirubin (TB). Two groups were observable in BA regarding HIFs: higher (hiHIF, considering as cutoff point a value higher than 3x the median of expression in IHC) and lower (loHIF). Patients with hiHIF-1α were older and presented increased levels of TB and direct-reacting serum bilirubin (DB) than loHIF-1α. Patients with hiHIF-2α presented CK19 expression lower than in loHIF-2α. The other variables were similar in subgroups HIFs. Conclusion: In BA there is hypoxia in the liver tissue, which seems to be progressive and associated with the disappearance of bile ducts and worsening biliary obstruction.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23369号 / 医博第4738号 / 新制||医||1051(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 武藤 学, 教授 松田 道行, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21337号 / 医博第4395号 / 新制||医||1031(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 武藤 学, 教授 富樫 かおり, 教授 川口 義弥 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21642号 / 医博第4448号 / 新制||医||1034(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 妹尾 浩, 教授 小川 誠司, 教授 坂井 義治 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM